Search

Your search keyword '"Ledermann, Jonathan A."' showing total 789 results
Start Over Author "Ledermann, Jonathan A."
789 results on '"Ledermann, Jonathan A."'

201. Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.

Author

Kanjanapan, Yada, primary, Lheureux, Stephanie, additional, May, Taymaa, additional, Wilson, Michelle K., additional, Bernardini, Marcus, additional, Shaw, Patricia Ann, additional, Vergote, Ignace, additional, Brenton, James D., additional, Provencher, Diane M., additional, McNeish, Iain A., additional, Ghatage, Prafull, additional, Ledermann, Jonathan A., additional, Colombo, Nicoletta, additional, Gourley, Charlie, additional, Weberpals, Johanne, additional, Ramsahai, Janelle, additional, Ricker, Nicole, additional, Accardi, Sarah, additional, Wang, Lisa, additional, and Oza, Amit M., additional

Published
2017
Full Text
View/download PDF

202. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

Author

Dougherty, Brian A., primary, Lai, Zhongwu, additional, Hodgson, Darren R., additional, Orr, Maria C.M., additional, Hawryluk, Matthew, additional, Sun, James, additional, Yelensky, Roman, additional, Spencer, Stuart K., additional, Robertson, Jane D., additional, Ho, Tony W., additional, Fielding, Anitra, additional, Ledermann, Jonathan A., additional, and Barrett, J. Carl, additional

Published
2017
Full Text
View/download PDF

207. Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference

Author

Jang, Ji Yon Agnes, primary, Yanaihara, Nozomu, additional, Pujade-Lauraine, Eric, additional, Mikami, Yoshiki, additional, Oda, Katsutoshi, additional, Bookman, Michael, additional, Ledermann, Jonathan, additional, Shimada, Muneaki, additional, Kiyokawa, Takako, additional, Kim, Byoung-Gie, additional, Matsumura, Noriomi, additional, Kaku, Tsunehisa, additional, Kuroda, Takafumi, additional, Nagayoshi, Yoko, additional, Kawabata, Ayako, additional, Iida, Yasushi, additional, Kim, Jae-Weon, additional, Quinn, Michael, additional, and Okamoto, Aikou, additional

Published
2017
Full Text
View/download PDF

209. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

Author

Ledermann, Jonathan A, primary, Harter, Philipp, additional, Gourley, Charlie, additional, Friedlander, Michael, additional, Vergote, Ignace, additional, Rustin, Gordon, additional, Scott, Clare, additional, Meier, Werner, additional, Shapira-Frommer, Ronnie, additional, Safra, Tamar, additional, Matei, Daniela, additional, Fielding, Anitra, additional, Bennett, Bryan, additional, Parry, David, additional, Spencer, Stuart, additional, Mann, Helen, additional, and Matulonis, Ursula, additional

Published
2016
Full Text
View/download PDF

210. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. (Articles)

Author

Kerr, David J, McArdle, Colin S, Ledermann, Jonathan, Taylor, Irving, Sherlock, David J, Schlag, Peter M, Buckels, John, Mayer, David, Cain, Dionne, and Stephens, Richard J

Subjects
Liver cancer -- Risk factors, Colorectal cancer -- Development and progression, Metastasis -- Development and progression, Metastasis -- Physiological aspects, Intravenous therapy -- Evaluation, Fluorouracil -- Dosage and administration, Leucovorin -- Dosage and administration, Drug therapy, Combination -- Dosage and administration
Published
2003

211. Mainstreamed genetic testing for women with ovarian cancer: first-year experience.

Author

Rahman, Belinda, Lanceley, Anne, Kristeleit, Rebecca S., Ledermann, Jonathan A., Lockley, Michelle, McCormack, Mary, Mould, Tim, and Side, Lucy

Abstract

Background: Ovarian cancer is the fifth most common cause of cancer death for women in the UK. Up to 18% of cases can be attributed to germline mutations in BRCA1 and BRCA2genes. Identifying patients who carry a BRCA mutation provides important information about potential response to treatment and eligibility for therapies such as poly ADP ribose polymerase (PARP) inhibitors. Implementation of systematic genetic testing of patients with ovarian cancer via oncology clinics (mainstreamed genetic testing, MGT) is increasing. Methods and results: This service evaluation reports on the first year of MGT at a tertiary oncology centre in London, UK. In total, 122 patients with high-grade non-mucinous ovarian cancer underwent BRCA germline testing via MGT. Eighteen patients (14.8%) were found to carry a deleterious BRCA1/BRCA2 mutation. Four BRCA carriers did not meet previous criteria for genetic testing and would have been missed. Six BRCA carriers accessed PARP inhibitors post-MGT. Only 22% of patients with a variant of unknown significance (VUS) were referred to clinical genetics services. Conclusions: MGT appears to be a feasible way of providing BRCA testing to patients with ovarian cancer. Greater clarity of how oncologists use VUS results is needed, as well as further research on psychosocial implications of MGT for patients with ovarian cancer, which may include somatic testing in the future. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

212. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.

Author

Hodgson, Darren R., Dougherty, Brian A., Lai, Zhongwu, Fielding, Anitra, Grinsted, Lynda, Spencer, Stuart, O'Connor, Mark J., Ho, Tony W., Robertson, Jane D., Lanchbury, Jerry S., Timms, Kirsten M., Gutin, Alexander, Orr, Maria, Jones, Helen, Gilks, Blake, Womack, Chris, Gourley, Charlie, Ledermann, Jonathan, and Barrett, J. Carl

Abstract

Background: Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2. We report exploratory analyses, including the long-term outcome of candidate biomarkers of sensitivity to olaparib in BRCA wild-type (BRCAwt) tumours.Methods: Tumour samples from an olaparib maintenance monotherapy trial (Study 19, D0810C00019; NCT00753545) were analysed. Analyses included classification of mutations in genes involved in homologous recombination repair (HRR), BRCA1 promoter methylation status, measurement of BRCA1 protein and Myriad HRD score.Results: Patients with BRCAm tumours gained most benefit from olaparib; a similar treatment benefit was also observed in 21/95 patients whose tumours were BRCAwt but had loss-of-function HRR mutations compared to patients with no detectable HRR mutations (58/95). A higher median Myriad MyChoice® HRD score was observed in BRCAm and BRCAwt tumours with BRCA1 methylation. Patients without BRCAm tumours derived benefit from olaparib treatment vs placebo although to a lesser extent than BRCAm patients.Conclusions: Ovarian cancer patients with tumours harbouring loss-of-function mutations in HRR genes other than BRCA1/2 may constitute a small, molecularly identifiable and clinically relevant population who derive treatment benefit from olaparib similar to patients with BRCAm. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

214. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Author

de Boer, Stephanie M, primary, Powell, Melanie E, additional, Mileshkin, Linda, additional, Katsaros, Dionyssios, additional, Bessette, Paul, additional, Haie-Meder, Christine, additional, Ottevanger, Petronella B, additional, Ledermann, Jonathan A, additional, Khaw, Pearly, additional, Colombo, Alessandro, additional, Fyles, Anthony, additional, Baron, Marie-Helene, additional, Kitchener, Henry C, additional, Nijman, Hans W, additional, Kruitwagen, Roy F, additional, Nout, Remi A, additional, Verhoeven-Adema, Karen W, additional, Smit, Vincent T, additional, Putter, Hein, additional, and Creutzberg, Carien L, additional

Published
2016
Full Text
View/download PDF

215. OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).

Author

Mackay, Helen, primary, Gallagher, Christopher J., additional, Parulekar, Wendy R., additional, Ledermann, Jonathan A., additional, Armstrong, Deborah Kay, additional, Gourley, Charlie, additional, Romero, Ignacio, additional, Feeney, Amanda, additional, Bessette, Paul, additional, Hall, Marcia, additional, Weberpals, Johanne Ingrid, additional, Hall, Geoff, additional, Lau, Susie K, additional, Gauthier, Philippe, additional, Fung-Kee-Fung, Michael, additional, Eisenhauer, Elizabeth A., additional, Winch, Chad, additional, Tu, Dongsheng, additional, and Provencher, Diane M., additional

Published
2016
Full Text
View/download PDF

217. Erratum: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Author

Drew, Yvette, primary, Ledermann, Jonathan, additional, Hall, Geoff, additional, Rea, Daniel, additional, Glasspool, Ros, additional, Highley, Martin, additional, Jayson, Gordon, additional, Sludden, Julieann, additional, Murray, James, additional, Jamieson, David, additional, Halford, Sarah, additional, Acton, Gary, additional, Backholer, Zoe, additional, Mangano, Raffaella, additional, Boddy, Alan, additional, Curtin, Nicola, additional, and Plummer, Ruth, additional

Published
2016
Full Text
View/download PDF

218. Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.

Author

Ledermann, Jonathan A., primary, Harter, Philipp, additional, Gourley, Charlie, additional, Friedlander, Michael, additional, Vergote, Ignace, additional, Rustin, Gordon J. S., additional, Scott, Clare L., additional, Meier, Werner, additional, Shapira-Frommer, Ronnie, additional, Safra, Tamar, additional, Matei, Daniela E., additional, Fielding, Anitra, additional, Spencer, Stuart, additional, Rowe, Philip, additional, Lowe, Elizabeth S., additional, and Matulonis, Ursula A., additional

Published
2016
Full Text
View/download PDF

219. TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Author

Michael, Agnieszka, primary, Lord, Rosemary, additional, Hall, Geoff, additional, Hanna, Louise, additional, Anand, Anjana, additional, Walther, Axel, additional, Nicum, Shibani, additional, Clamp, Andrew R., additional, Kristeleit, Rebecca Sophie, additional, Hackshaw, Alan, additional, Parmar, Gita, additional, Ngai, Yen, additional, Farrelly, Laura, additional, Essapen, Sharadah, additional, McNeish, Iain A., additional, Harrop, Richard, additional, and Ledermann, Jonathan A., additional

Published
2016
Full Text
View/download PDF

220. Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial.

Author

Pujade-Lourraine, Eric, primary, Colombo, Nicoletta, additional, Disis, Mary L., additional, Fujiwara, Keiichi, additional, Ledermann, Jonathan A., additional, Mirza, Mansoor Raza, additional, Richardson, Gary Edward, additional, Beck, J. Thaddeus, additional, Gaillard, Stephanie, additional, Haney, Patricia, additional, Shnaidman, Michael, additional, Morozov, Alexei, additional, and Monk, Bradley J., additional

Published
2016
Full Text
View/download PDF

221. Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Author

Matulonis, Ursula A., primary, Harter, Philipp, additional, Gourley, Charlie, additional, Friedlander, Michael, additional, Vergote, Ignace, additional, Rustin, Gordon, additional, Scott, Clare, additional, Meier, Werner, additional, Shapira‐Frommer, Ronnie, additional, Safra, Tamar, additional, Matei, Daniela, additional, Fielding, Anitra, additional, Spencer, Stuart, additional, Parry, David, additional, Grinsted, Lynda, additional, and Ledermann, Jonathan A., additional

Published
2016
Full Text
View/download PDF

222. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Author

Drew, Yvette, primary, Ledermann, Jonathan, additional, Hall, Geoff, additional, Rea, Daniel, additional, Glasspool, Ros, additional, Highley, Martin, additional, Jayson, Gordon, additional, Sludden, Julieann, additional, Murray, James, additional, Jamieson, David, additional, Halford, Sarah, additional, Acton, Gary, additional, Backholer, Zoe, additional, Mangano, Raffaella, additional, Boddy, Alan, additional, Curtin, Nicola, additional, and Plummer, Ruth, additional

Published
2016
Full Text
View/download PDF

223. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Author

Ledermann, Jonathan A, primary, Embleton, Andrew C, additional, Raja, Fharat, additional, Perren, Timothy J, additional, Jayson, Gordon C, additional, Rustin, Gordon J S, additional, Kaye, Stan B, additional, Hirte, Hal, additional, Eisenhauer, Elizabeth, additional, Vaughan, Michelle, additional, Friedlander, Michael, additional, González-Martín, Antonio, additional, Stark, Daniel, additional, Clark, Elizabeth, additional, Farrelly, Laura, additional, Swart, Ann Marie, additional, Cook, Adrian, additional, Kaplan, Richard S, additional, and Parmar, Mahesh K B, additional

Published
2016
Full Text
View/download PDF

225. Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer

Author

Lemech, Charlotte R., primary, Ensell, Leah, additional, Paterson, Jennifer C., additional, Eminowicz, Gemma, additional, Lowe, Helen, additional, Arora, Rupali, additional, Arkenau, Hendrik-Tobias, additional, Widschwendter, Martin, additional, MacDonald, Nicola, additional, Olaitan, Adeola, additional, Mould, Tim, additional, Meyer, Tim, additional, Hartley, John, additional, Mitra, Anita, additional, Ledermann, Jonathan A., additional, McCormack, Mary, additional, and Kristeleit, Rebecca S., additional

Published
2016
Full Text
View/download PDF

226. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy

Author

Milani, Andrea, primary, Kristeleit, Rebecca, additional, McCormack, Mary, additional, Raja, Fharat, additional, Luvero, Daniela, additional, Widschwendter, Martin, additional, MacDonald, Nicola, additional, Mould, Tim, additional, Olatain, Adeola, additional, Hackshaw, Allan, additional, and Ledermann, Jonathan A., additional

Published
2016
Full Text
View/download PDF

231. Update on first-line treatment of advanced ovarian carcinoma

Author

Ledermann, Jonathan and Kemp

Subjects
International Journal of Women's Health
Abstract

Z Kemp,1 JA Ledermann1,21Department of Oncology, University College London Hospitals, 2University College London Cancer Institute, University College London, London, United KingdomAbstract: Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patients relapse. Maximal debulking surgery and chemotherapy with a platinum doublet have remained the standard of care for many years and new approaches are imperative. Recent clinical trials have given grounds for hope. Neoadjuvant chemotherapy, intraperitoneal delivery, and dose-dense strategies have all shown promising results, as has the targeting of angiogenesis. A greater understanding of the molecular landscape of ovarian cancer is helping to identify new treatment options. In this review, we will highlight the key trials and recent progress in these areas.Keywords: ovarian cancer, first-line therapy, neoadjuvant, intraperitoneal, dose-dense, angiogenesis

Published
2013

232. Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).

Author

Arend, Rebecca Christian, Monk, Bradley J., Shapira-Frommer, Ronnie, Secord, Angeles Alvarez, Herzog, Thomas J., Tewari, Krishnansu Sujata, Ledermann, Jonathan A., Rachmilewitz Minei, Tamar, Buyse, Marc E., Haggerty, Ashley, Alvarez, Edwin A, Amit, Amnon, Muller, Carolyn, Casado Herraez, Antonio, Holman, Laura L., Cohen, Joshua, Huang, Marilyn, Yachnin, Adelya, Harats, Dror, and Penson, Richard T.

Published
2023
Full Text
View/download PDF

233. European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015

Author

du Bois, Andreas, primary, Reuss, Alexander, additional, Pujade-Lauraine, Eric, additional, Pignata, Sandro, additional, Ledermann, Jonathan, additional, Casado, Antonio, additional, Sehouli, Jalid, additional, Mirza, Mansoor, additional, Colombo, Nicoletta, additional, Marth, Christian, additional, Witteveen, Els, additional, Del Campo, Jose, additional, Calvert, Paula, additional, Aravantinos, Gerassimos, additional, Vardar, Mehmet Ali, additional, van der Zee, Ate G.J., additional, Korach, Jacob, additional, Taskiran, Cagatay, additional, Fehr, Mathias, additional, Glasspool, Ros, additional, Pfisterer, Jacobus, additional, Cibula, David, additional, and Vergote, Ignace, additional

Published
2015
Full Text
View/download PDF

234. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Author

McCluggage, W Glenn, primary, Judge, Meagan J, additional, Clarke, Blaise A, additional, Davidson, Ben, additional, Gilks, C Blake, additional, Hollema, Harry, additional, Ledermann, Jonathan A, additional, Matias-Guiu, Xavier, additional, Mikami, Yoshiki, additional, Stewart, Colin JR, additional, Vang, Russell, additional, and Hirschowitz, Lynn, additional

Published
2015
Full Text
View/download PDF

235. Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations inBRCA1orBRCA2are biologically similar and sensitive to PARP inhibition

Author

Dougherty, Brian, primary, Lai, Zhongwu, additional, Ledermann, Jonathan A., additional, Robertson, Jane D., additional, Ho, Tony W., additional, Wu, Wenting, additional, Hodgson, Darren R., additional, Orr, Maria C M, additional, O'Connor, Mark J., additional, Hawryluk, Matthew J., additional, Brennan, Timothy A., additional, Yelensky, Roman, additional, Sun, James X., additional, and Barrett, J Carl, additional

Published
2015
Full Text
View/download PDF

236. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Author

Oza, Amit M, primary, Cook, Adrian D, additional, Pfisterer, Jacobus, additional, Embleton, Andrew, additional, Ledermann, Jonathan A, additional, Pujade-Lauraine, Eric, additional, Kristensen, Gunnar, additional, Carey, Mark S, additional, Beale, Philip, additional, Cervantes, Andrés, additional, Park-Simon, Tjoung-Won, additional, Rustin, Gordon, additional, Joly, Florence, additional, Mirza, Mansoor R, additional, Plante, Marie, additional, Quinn, Michael, additional, Poveda, Andrés, additional, Jayson, Gordon C, additional, Stark, Dan, additional, Swart, Ann Marie, additional, Farrelly, Laura, additional, Kaplan, Richard, additional, Parmar, Mahesh K B, additional, and Perren, Timothy J, additional

Published
2015
Full Text
View/download PDF

239. The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership

Author

Marth, Christian, primary, du Bois, Andreas, additional, Schauer, Christian, additional, Casado, Antonio, additional, Vergote, Ignace, additional, del Campo, José Maria, additional, Goudopoulou, Athina, additional, Pujade-Lauraine, Eric, additional, Bruchim, Ilan, additional, Colombo, Nicoletta, additional, Pignata, Sandro, additional, Ledermann, Jonathan, additional, Chekerov, Radoslav, additional, Raza Mirza, Mansoor, additional, Westermann, Anneke, additional, Glasspool, Ros, additional, Taskiran, Cagatay, additional, Fehr, Mathias, additional, and Cibula, David, additional

Published
2015
Full Text
View/download PDF

240. Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ± bevacizumab (BEV) for ovarian cancer (OC).

Author

Gonzalez-Martin, Antonio, primary, Oza, Amit M., additional, Embleton, Andrew C., additional, Pfisterer, Jacobus, additional, Ledermann, Jonathan A., additional, Pujade-Lauraine, Eric, additional, Kristensen, Gunnar, additional, Bertrand, Monique A, additional, Beale, Philip James, additional, Cervantes-Ruiperez, Andres, additional, Kent, Emma, additional, Kaplan, Richard S., additional, Parmar, Mahesh M K, additional, Scotto, Nana, additional, Mitchell, Lada, additional, and Perren, Timothy, additional

Published
2015
Full Text
View/download PDF

241. Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.

Author

Creutzberg, Carien L., primary, de Boer, Stephanie M., additional, Putter, Hein, additional, Powell, Melanie, additional, Mileshkin, Linda R., additional, Katsaros, Dionyssios, additional, Bessette, Paul, additional, Haie-Meder, Christine, additional, Ledermann, Jonathan A., additional, Ottevanger, P. B., additional, Khaw, Pearly, additional, Colombo, Alessandro, additional, Fyles, Anthony W., additional, Baron, Marie-Helene, additional, Nijman, Hans W., additional, Nout, Remi A., additional, Smit, Vincent T.H.B.M., additional, Verhoeven-Adema, Karen, additional, Kruitwagen, Roy F.P.M., additional, and Kitchener, Henry C., additional

Published
2015
Full Text
View/download PDF

242. Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).

Author

Gore, Martin Eric, primary, Hackshaw, Allan, additional, Brady, William E, additional, Penson, Richard T., additional, Zaino, Richard J, additional, McCluggage, W. Glenn, additional, Ganesan, Raji, additional, Wilkinson, Nafisa, additional, Perren, Timothy, additional, Montes, Ana, additional, Summers, Jeffrey, additional, Lord, Rosemary, additional, Dark, Graham G., additional, Rustin, Gordon J. S., additional, Mackean, Melanie J., additional, Reed, Nicholas, additional, Kehoe, Sean, additional, Christensen, Helen, additional, Ledermann, Jonathan A., additional, and Gershenson, David Marc, additional

Published
2015
Full Text
View/download PDF

243. Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

Author

Matulonis, Ursula, primary, Friedlander, Michael, additional, Du Bois, Andreas, additional, Gourley, Charlie, additional, Vergote, Ignace, additional, Rustin, Gordon J. S., additional, Scott, Clare L., additional, Meier, Werner, additional, Shapira-Frommer, Ronnie, additional, Safra, Tamar, additional, Matei, Daniela, additional, Fielding, Anitra, additional, McMurtry, Emma, additional, Spencer, Stuart, additional, Mann, Helen, additional, Parry, David, additional, and Ledermann, Jonathan A., additional

Published
2015
Full Text
View/download PDF

244. Genomic characterization of long-term responders to olaparib.

Author

Lheureux, Stephanie, primary, Ledermann, Jonathan A., additional, Runswick, Sarah, additional, Hodgson, Darren R, additional, Timms, Kirsten, additional, Lanchbury, Jerry S., additional, Kaye, Stanley B., additional, Gourley, Charlie, additional, Bowtell, David, additional, Kohn, Elise C., additional, Scott, Clare L., additional, Matulonis, Ursula, additional, Panzarella, Tony, additional, Dougherty, Brian Andrew, additional, Barrett, J Carl, additional, Lai, Zhongwu, additional, o'Connor, Mark, additional, Robertson, Jane D., additional, Ho, Tony Weishiu, additional, and Oza, Amit M., additional

Published
2015
Full Text
View/download PDF

245. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).

Author

Ruers, Theo, primary, Punt, Cornelis J. A., additional, van Coevorden, Frits, additional, Pierie, Jean-Pierre, additional, Borel Rinkes, Inne, additional, Ledermann, Jonathan A., additional, Poston, Graeme John, additional, Bechstein, Wolf O., additional, Lentz, Marie-Ange, additional, Mauer, Murielle E., additional, Van Cutsem, Eric, additional, Lutz, Manfred P., additional, and Nordlinger, Bernard, additional

Published
2015
Full Text
View/download PDF

247. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary

Author

Glasspool, Rosalind M., Martin, Antonio Gonzalez, Millan, David, Lorusso, Domenica, Avall-Lundqvist, Elisabeth, Hurteau, Jean A., Davis, Alison, Hilpert, Felix, Kim, Jae-Weon, Alexandre, Jerome, Ledermann, Jonathan A., Glasspool, Rosalind M., Martin, Antonio Gonzalez, Millan, David, Lorusso, Domenica, Avall-Lundqvist, Elisabeth, Hurteau, Jean A., Davis, Alison, Hilpert, Felix, Kim, Jae-Weon, Alexandre, Jerome, and Ledermann, Jonathan A.

Published
2014

248. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.

Author

Satoh, Toyomi, Takei, Yuji, Treilleux, Isabelle, Devouassoux-Shisheboran, Mojgan, Ledermann, Jonathan, Viswanathan, Akila N, Mahner, Sven, Provencher, Diane M, Mileshkin, Linda, Åvall-Lundqvist, Elisabeth, Pautier, Patricia, Reed, Nicholas Simon, Fujiwara, Keiichi, Satoh, Toyomi, Takei, Yuji, Treilleux, Isabelle, Devouassoux-Shisheboran, Mojgan, Ledermann, Jonathan, Viswanathan, Akila N, Mahner, Sven, Provencher, Diane M, Mileshkin, Linda, Åvall-Lundqvist, Elisabeth, Pautier, Patricia, Reed, Nicholas Simon, and Fujiwara, Keiichi

Abstract

Small cell carcinoma of the cervix (SCCC) is a rare histological entity of uterine cervical cancer. Compared with other common histological types, squamous cell carcinoma or adenocarcinoma, the outcome of SCCC is poor because of the high incidence of nodal or distant metastasis even with early stage. In this review, current consensus of epidemiology, pathology, and initial treatment for SCCC will be discussed.

Published
2014
Full Text
View/download PDF

249. Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.

Author

Glasspool, Rosalind M, González Martín, Antonio, Millan, David, Lorusso, Domenica, Åvall-Lundqvist, Elisabeth, Hurteau, Jean A, Davis, Alison, Hilpert, Felix, Kim, Jae-Weon, Alexandre, Jérôme, Ledermann, Jonathan A, Glasspool, Rosalind M, González Martín, Antonio, Millan, David, Lorusso, Domenica, Åvall-Lundqvist, Elisabeth, Hurteau, Jean A, Davis, Alison, Hilpert, Felix, Kim, Jae-Weon, Alexandre, Jérôme, and Ledermann, Jonathan A

Abstract

Squamous cell carcinoma of the ovary is a rare complication of mature cystic teratoma. The epidemiology, pathology, diagnosis, and management of this rare tumor are reviewed. Clinical characteristics, preoperative imaging, and tumor markers may help to predict malignancy preoperatively. Complete cytoreduction should be the aim of surgery. The prognosis for stage 1A disease is good, but for women with advanced or recurrent disease, it is very poor and has not improved in recent years. At present, there are insufficient data to provide clear guidance on the optimal management strategy for advanced disease, and there is a need to gain an understanding of the biology and to develop novel effective therapies. This will require coordinated international collaboration.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results